September 26, 2017
Moderna Announces Publication in Molecular Therapy Characterizing Potent Immune Response Generated by Its mRNA Prophylactic Vaccines
September 14, 2017
Moderna Announces Pipeline and Corporate Update
August 03, 2017
Industry Veteran Juan Andres Joins Moderna as Senior Vice President of Late Stage Technical Development and Manufacturing
July 27, 2017
Moncef M. Slaoui, Ph.D. Joins Moderna’s Board of Directors
July 27, 2017
Moderna Provides Update on mRNA Rare Disease Research and Development Strategy
July 13, 2017
Publication in Cell Demonstrates Moderna’s Zika mRNA Vaccine Prevents In Utero Transmission of Zika Virus in Mice, Protects Against Zika-Related Congenital Damage
May 03, 2017
Melissa J. Moore, Ph.D., Chief Scientific Officer, mRNA Research Platform at Moderna, Elected to National Academy of Sciences
April 27, 2017
Moderna Announces Positive Interim Phase 1 Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA-1440, Induces High Levels of Immunogenicity
February 22, 2017
Moderna Appoints Israel Ruiz to its Board of Directors
January 09, 2017
Moderna Provides Pipeline and Full-Year Corporate Update